NGM — NGM Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Brief: NGM Announces Completion Of Enrollment In Phase 2 Catalina Study Of Ngm621 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
NGM Biopharma rises on starting early stage study for cancer therapy
Brief: NGM Bio Announces Initiation Of Phase 1/2 Clinical Study Of NGM707
NGM Biopharma rises on amended drug development pact with Merck
Brief: Ngm Amends Collaboration With Merck To Focus Primarily On Advancing Novel Medicines For Retinal And Cardiovascular And Metabolic Diseases
U.S. RESEARCH ROUNDUP-Cimarex Energy, Dollar General, Werewolf Therapeutics
U.S. STOCKS ON THE MOVE-Scopus Biopharma, Beyond Meat, Puxin Ltd, Veritiv
89bio Inc: Falls as rival NASH drug fails study
U.S. STOCKS ON THE MOVE-Virgin Galactic, Aptorum Group, Tesla, NGM Biopharma
U.S. STOCKS ON THE MOVE-NGM Biopharmaceuticals, Virgin Galactic, Coinbase
NGM Biopharma: Set to nearly halve as liver disease trial fails
NASDAQ RESUMED AT 07:31 AM
Brief: NGM Bio Reports Topline Results From 24-Week Phase 2B Alpine 2/3 Study Of Aldafermin In Nash
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:56 AM
NGM Biopharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ngm Bio Provides Business Highlights And Reports First Quarter 2021 Financial Results
Brief: Ngm Announces Nomination Of Roger M. Perlmutter For Election To Its Board Of Directors
Brief: NGM Bio Reports Q4 2020 Financial Results
Brief: Ngm Bio Initiates Expansion Of Ongoing Phase 1B Proof-Of-Concept Study Of Ngm120 In Patients With Metastatic Pancreatic Cancer